Horizon scanning: Positive data from phase III (ADVANCE) trial of peginterferon beta-1a for relapsing-remitting multiple sclerosis

Source: Reuters Area: News Biogen Idec has released the primary efficacy analysis and safety data from its phase III pivotal clinical trial, ADVANCE of peginterferon beta-1a dosed every two weeks or every four weeks for relapsing-remitting multiple sclerosis (RRMS). Peginterferon beta-1a is a new molecular entity in which interferon beta-1a is pegylated to extend its half-life and prolong its exposure in the body, enabling a less frequent dosing schedule.   The two-year phase III ADVANCE clinical trial is a global, multi-centre randomised, double-blind, parallel-group, placebo-controlled study conducted in 1516 patients with RRMS. It compared peginterferon beta-1a, 125 mcg administered subcutaneously every 2 weeks or every 4 weeks with placebo. The primary endpoint is annualised relapse rate (ARR). The analysis for all primary and secondary efficacy endpoints occurs at one year. After the first year, patients on placebo are re-randomised to one of the peginterferon beta-1a arms for the duration of ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news